# Effects of Aqualief® in Patients With Xerostomia as Consequence of Radiotherapy for Head and Neck Cancer

> **NCT03601962** · NA · TERMINATED · sponsor: **Helsinn Healthcare SA** · enrollment: 100 (actual)

## Conditions studied

- Xerostomia
- Asialia
- Hyposalivation
- Mouth Dryness

## Interventions

- **DIETARY_SUPPLEMENT:** Aqualief
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03601962
- **Lead sponsor:** Helsinn Healthcare SA
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-31
- **Primary completion:** 2020-01-22
- **Final completion:** 2020-01-22
- **Target enrollment:** 100 (ACTUAL)
- **Why stopped:** Low enrolment rate
- **Last updated:** 2020-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03601962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03601962, "Effects of Aqualief® in Patients With Xerostomia as Consequence of Radiotherapy for Head and Neck Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03601962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*